



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 11/8/06 Signature: GK
(Ginny Blundell)

1636
Docket No.: APBI-P04-035
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Baltimore et al.

Application No.: 10/037415

Confirmation No.: 7747

Filed: January 4, 2002

Art Unit: 1636

For: NUCLEAR FACTORS ASSOCIATED WITH
TRANSCRIPTIONAL REGULATION

Examiner: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h),


the filing of this Supplemental Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. APBI-P04-035.

Dated: 1/18/06

Respectfully submitted,

By 

Melissa S. Rones, Ph.D.

Registration No.: 54,408
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/037415
				Filing Date	January 4, 2002
				First Named Inventor	David Baltimore
				Art Unit	1636
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	APBI-P04-035

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	CD	Baldwin, et al., "Two transcription factors, NF- κ B and H2TF1, interact with a single regulatory sequence in the class I major histocompatibility complex promoter", Proc. Natl. Acad. Sci., 85, pages 723-727 (1988)			
	CE	Bielinska, et al., "Regulation of Gene Expression with Double-Stranded Phosphorothioate Oligonucleotides", Science, 250, pages 997-1000 (1990)			
	CF	Chu, et al., "Electroporation for the efficient transfection of mammalian cells with DNA", Nucleic Acids Research, 15(3) pages 1311-1326 (1987)			
	CG	Eck, et al., "Inhibition of Phorbol ester-induced cellular adhesion by competitive binding of NF- κ B in vivo", Molecular and Cellular Biology, 13(10), pages 6530-6536 (1993) Abstract			
	CH	Griffith, et al., "Targeted blood levels of cyclosporine for cardiac transplantation", J. Thorac Cardiovasc Surg, 88, pages 952-957 (1984)			
	CI	Hai, et al., "Analysis of the Role of the Transcription Factor ATF in the Assembly of a Functional Preinitiation Complex", Cell, 54, pages 1043-1051 (1988)			
	CJ	Holschermann, et al., "Cyclosporin A Inhibits Monocyte Tissue Factor Activation in Cardiac Transplant Recipients", Circulation, 96, pages 4232-4238 (1997)			
	CK	Li, et al., "Multiple Hepatic trans-Acting Factors Are Required for In Vitro Transcription of the Human Alpha-1-Antitrypsin Gene", Molecular and Cellular Biology, 8(10), pages 4362-4369 (1988)			
	CL	Molecular Biology of THE CELL, 2nd Ed. (1989) page 423			
	CM	Schorpp, et al., "Hepatocyte-specific Promoter Element HP1 of the Xenopus Albumin Gene Interacts with Transcriptional Factors of Mammalian Hepatocytes", J. Mol. Biol., 202, pages 307-320 (1988)			
	CN	Schreck, et al., "Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells", Journal of Experimental Medicine, 175, pages 1181-1194 (1992)			
	CO	Staal, et al., "Intracellular thiols regulate activation of nuclear factor κ B and transcription of human immunodeficiency virus", Proc. National Academy Sci., 87, pages 9943-9947 (1990)			
	CP	Tanaka, et al., "Sequence-specific interaction of α - β -anomeric double-stranded DNA with the p50 subunit of NF κ B: application to the decoy approach", Nucleic Acids Research, 22(15),			
Examiner Signature			Date Considered		



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<i>Complete If Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/037415
(Use as many sheets as necessary)				Filing Date	January 4, 2002
				First Named Inventor	David Baltimore
				Art Unit	1636
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	APBI-P04-035

	pages 3069-3074 (1994)	
--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/92 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/037415

Attorney Docket No.: APBI-P04-035

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on

1/18/06

Date

Signature

Ginny Blundell

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 951-7000

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS by Applicant – Form PTO/SB/08 (13 References)
References (13, CD-CP)